Format

Send to:

Choose Destination
See comment in PubMed Commons below
Leuk Res. 2008 Nov;32(11):1715-23. doi: 10.1016/j.leukres.2008.03.028. Epub 2008 May 5.

Prognostic value of circulating CD34+ cells in myelodysplastic syndromes.

Author information

  • 1Department of Transfusion Medicine and Division of Hematology, Niguarda Ca' Granda Hospital, Milan, Italy. clara.cesana@ospedaleniguarda.it

Abstract

We studied circulating (C)CD34(+) cells by flow cytometry in 96 patients with myelodysplastic syndromes (MDS) at diagnosis, and in a subset of 35 cases during follow-up. CCD34(+) counts were stratified within both International Prognostic Scoring System (IPSS) and World Health Organization (WHO) categories. Counts >10/microl were associated with poorer leukemia-free survival, a prognostic value for evolution independent from that of WHO, and a higher progression probability within intermediate-risk IPSS and WHO classes. When serial measurements were performed, counts >10/microl more frequently correlated to evolution. Separating newly diagnosed patients on the basis of 10/microl cut-off of circulating CD34(+) cells retains prognostic utility, especially in intermediate-risk MDS.

PMID:
18456323
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk